Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Contour Neurovascular System™ ContiNued Access Investigational Device EXempTion (IDE) Trial (NEXT Trial)

NCT06693011 · View on ClinicalTrials.gov ↗

Study Summary

The goal of this clinical trial is to collect additional data to demonstrate if the Contour Neurovascular System (CNS) is a safe and effective treatment of wide-necked, saccular, intracranial aneurysms. Participants will: Undergo treatment with the Contour Neurovascular System Complete follow-up visits at 1month, 12months, and 24 months, following their procedure Report any adverse events to their study team

Conditions Studied

Interventions

  • DEVICE Contour Neurovascular System Treatment Attempt

Study Locations (4)

New York

  • University at Buffalo Neurosurgery — Buffalo
  • Stony Brook University — Stony Brook

Pennsylvania

  • University of Pennsylvania — Philadelphia

Washington

  • Swedish Neuroscience Institute — Seattle

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2025-06-10
Est. Completion 2030-01
Phase NA

Sponsor

Cerus Endovascular

2 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06693011

The ClinicalTrials.gov registry entry for NCT06693011 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cerus Endovascular, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Cerebral Aneurysms appearing as the primary indexed condition, and to 1 intervention — of which Contour Neurovascular System Treatment Attempt is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06693011 reports 4 study locations spanning 3 distinct geographic areas — top geographies include New York, Pennsylvania, Washington. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06693011 about?

NCT06693011 is a clinical study titled "Contour Neurovascular System™ ContiNued Access Investigational Device EXempTion (IDE) Trial (NEXT Trial)". The goal of this clinical trial is to collect additional data to demonstrate if the Contour Neurovascular System (CNS) is a safe and effective treatment of wide-necked, saccular, intracranial aneurysms. Participants will: Undergo treatment with the Contour Neurovascular System Complete follow-up v...

What is the current status of trial NCT06693011?

This trial is currently recruiting. It is a NA study. The enrollment target is 250 participants. The study started on 2025-06-10. Estimated completion is 2030-01.

What conditions does trial NCT06693011 study?

This clinical trial studies the following conditions: Cerebral Aneurysms. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06693011?

The interventions under investigation include: Contour Neurovascular System Treatment Attempt (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06693011?

This trial is sponsored by Cerus Endovascular, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06693011 being conducted?

This trial has 4 study locations across New York, Pennsylvania, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial